Sequentify and Bio Molecular Systems Join Forces for Advanced NGS Library Prep
In an exciting collaboration within the life sciences sector, Sequentify and Bio Molecular Systems (BMS) have unveiled the InfiniSeq™ Protocol designed for the Myra® liquid handling system. This groundbreaking protocol, now accessible for download from the BMS Script Library, aims to transform the landscape of next-generation sequencing (NGS) library preparation by making it faster, simpler, and more scalable.
The InfiniSeq Protocol merges Sequentify's state-of-the-art four-step targeted sequencing chemistry with BMS's precision automation capabilities. This union offers a streamlined solution for high-throughput library preparation, enabling laboratories to efficiently prepare up to 96 indexed libraries in a single run. This protocol is crafted to reduce hands-on time and eliminate the need for intermediate cleanup, which significantly boosts productivity.
"By marrying our InfiniSeq Protocol with the Myra system, labs can now perform automated NGS preparation in a matter of minutes, requiring minimal training while significantly increasing throughput and minimizing errors," commented Tamir Biezuner, Chief Scientific Officer and Co-founder of Sequentify. He emphasized that this efficiency enables laboratories to expand genomic testing capabilities without the necessity for costly, specialized robotic infrastructure.
Albert Wijngaard, Vice President of Global Sales at BMS, echoed these sentiments, stating that the Myra's speed and ease of use enable laboratories to save crucial time while ensuring high-quality outcomes. By utilizing the InfiniSeq Protocol in conjunction with the Myra system, labs can confidently automate their processes without facing steep learning curves or technical hinderances.
This revolutionary protocol has found applications in both research and clinical settings, particularly in Sequentify's myeloid malignancy and oncology panels. These panels are being adopted by leading institutions to decentralize genomic testing, bringing advanced testing capabilities closer to various healthcare providers.
The InfiniSeq Myra Protocol is part of Sequentify's mission to facilitate population-wide genomic sequencing by offering the most efficient laboratory solutions available. Since its founding in 2021, Sequentify has continually addressed industry pain points directly, focusing on sample preparation and software solutions that simplify and enhance genomic testing. Their product lineup includes panels for oncology, screening applications, and infectious diseases, with a strong emphasis on the clinical market.
Sequentify, based in Rehovot, Israel, has made significant strides in the biotechnology landscape through its commitment to transforming and democratizing genomic testing practices.
Similarly, Bio Molecular Systems (BMS), established in 2010, has been at the forefront of life sciences innovation. With a background rooted in the former Corbett Life Sciences company, BMS is known for designing, manufacturing, and distributing high-quality instrumentation that meets the demands of the life sciences industry. Their rigorous focus on customer feedback and rapid in-house innovation has allowed them to maintain a strong market position with products that are not only robust but also user-friendly.
For more information regarding the InfiniSeq Protocol and its applications, please visit the BMS website where the protocol is now available in the Myra Script Library.
The InfiniSeq Protocol merges Sequentify's state-of-the-art four-step targeted sequencing chemistry with BMS's precision automation capabilities. This union offers a streamlined solution for high-throughput library preparation, enabling laboratories to efficiently prepare up to 96 indexed libraries in a single run. This protocol is crafted to reduce hands-on time and eliminate the need for intermediate cleanup, which significantly boosts productivity.
"By marrying our InfiniSeq Protocol with the Myra system, labs can now perform automated NGS preparation in a matter of minutes, requiring minimal training while significantly increasing throughput and minimizing errors," commented Tamir Biezuner, Chief Scientific Officer and Co-founder of Sequentify. He emphasized that this efficiency enables laboratories to expand genomic testing capabilities without the necessity for costly, specialized robotic infrastructure.
Albert Wijngaard, Vice President of Global Sales at BMS, echoed these sentiments, stating that the Myra's speed and ease of use enable laboratories to save crucial time while ensuring high-quality outcomes. By utilizing the InfiniSeq Protocol in conjunction with the Myra system, labs can confidently automate their processes without facing steep learning curves or technical hinderances.
This revolutionary protocol has found applications in both research and clinical settings, particularly in Sequentify's myeloid malignancy and oncology panels. These panels are being adopted by leading institutions to decentralize genomic testing, bringing advanced testing capabilities closer to various healthcare providers.
The InfiniSeq Myra Protocol is part of Sequentify's mission to facilitate population-wide genomic sequencing by offering the most efficient laboratory solutions available. Since its founding in 2021, Sequentify has continually addressed industry pain points directly, focusing on sample preparation and software solutions that simplify and enhance genomic testing. Their product lineup includes panels for oncology, screening applications, and infectious diseases, with a strong emphasis on the clinical market.
Sequentify, based in Rehovot, Israel, has made significant strides in the biotechnology landscape through its commitment to transforming and democratizing genomic testing practices.
Similarly, Bio Molecular Systems (BMS), established in 2010, has been at the forefront of life sciences innovation. With a background rooted in the former Corbett Life Sciences company, BMS is known for designing, manufacturing, and distributing high-quality instrumentation that meets the demands of the life sciences industry. Their rigorous focus on customer feedback and rapid in-house innovation has allowed them to maintain a strong market position with products that are not only robust but also user-friendly.
For more information regarding the InfiniSeq Protocol and its applications, please visit the BMS website where the protocol is now available in the Myra Script Library.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.